- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01680601
Remote Ischaemic Preconditioning in Children Undergoing Cardiac Surgery
Effect of Remote Ischaemic Preconditioning in Cardiac Dysfunction and End-organ Injury Following Cardiac Surgery With Cardiopulmonary Bypass in Children.
Surgical correction of congenital heart defects in children requires the utilization of cardiopulmonary bypass, a technique that temporarily substitutes heart and lung functions during surgery. During this process the patient´s circulation is controlled by a bypass machine which provides several functions:
- Controls the patient's blood flow by pumping of blood in the patient's body.
- Controls the correct oxygen levels in the patient's blood.
- Regulates the temperature and fluid level of the blood. This process triggers negative responses in the heart and throughout the whole body, potentially resulting in injury to the heart and other organs such as brain, kidneys and lungs.
Remote ischaemic preconditioning (RIPC) describes a procedure that could potentially reduce the injury to heart muscle during cardiac surgery. The procedure consists of the inflation of a blood pressure cuff on the child's leg for three 5 minute cycles. This process acts by briefly reducing blood flow to the leg muscle, which will then activate the body´s own protective mechanisms and thereby reduce heart injury.
Several animal studies have been used to help the understanding of the mechanisms behind this process, and trials in human adults have showed optimistic results; however evidence regarding the paediatric population is limited and necessary since children present different basal profiles, risks and requirements.
The investigators propose a randomized clinical trial assessing the efficacy of RIPC to provide protection against injury to the heart and other organs in children going through cardiac surgery using CPB at the Royal Hospital for Sick Children. The research project will have a translational approach, integrating basic molecular mechanisms to clinical outcome. The investigators hope it will allow the understanding and utilisation of the patient´s own protective mechanisms, reducing CPB-related injury and ultimately improving patient outcome.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Glasgow, United Kingdom, G3 8SJ
- Royal Hospital for Sick Children - Yorkhill
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children undergoing cardiac surgery for correction of congenital heart defects utilizing cardiopulmonary bypass and cold blood cardioplegia strategy of myocardial protection.
- Children whose parents understand the child's condition, the purpose of the study and are willing to participate.
Exclusion Criteria:
- Children whose parents either are unwilling or do not have sufficient understanding of the study.
- Emergency operations, where there is insufficient time to establish the study protocol.
- Premature children presenting a corrected gestational age under 35 weeks.
- Presence of extracardiac abnormalities, apart from cases of Down and DiGeorge syndromes which will be included.
- Patients with known viral blood infections (e.g. HIV, Hepatitis B) or severe congenital infection.
- Patients with severe preoperative brain injury.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: RIPC group
Patients assigned to this arm will go through a remote ischaemic preconditioning (RIPC)protocol
|
RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure.
This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
|
PLACEBO_COMPARATOR: Control
Patients assigned to this arm will not receive the intervention, however the protocol will be applied to a wooden block in order to maintain blinding to relatives and investigators.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of the final cardiac injury after cardiopulmonary bypass assessed by markers of cardiac injury and echocardiography.
Time Frame: Pre and post operatively (immediately before and after surgery, 24 and 48 hours after surgery)
|
Echocardiography assessment will take place before surgery, 24 and 48 hours after surgery.
Blood markers of cardiac injury: B-type natriuretic peptide and Troponin will be measured before surgery, immediately after surgery, 24 and 48 hours after surgery in order to establish changes in the markers between the mentioned pre and post-operative time points.
|
Pre and post operatively (immediately before and after surgery, 24 and 48 hours after surgery)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Protein and mRNA expression in the cardiac tissue related to the preconditioning process.
Time Frame: Expression assessed at the time of tissue extraction
|
Cardiac tissue will be obtained only from patients who require tissue excision as part of the surgical procedure.
Protein and mRNA expression will be assessed after extraction.
|
Expression assessed at the time of tissue extraction
|
End organ damage assessment by measurement of markers relevant to lung and kidney function and evaluate a possible benefit from preconditioning.
Time Frame: Pre and post operatively (immediately before and after surgery, 24 and 48 hours after surgery)
|
Blood markers (creatinin, cystatin C, Neutrophil gelatinase associated lipocalin,cGMP and Phosphodiesterase 5)will be measured before surgery, immediately after surgery, 24 and 48 hours after surgery in order to establish changes in the markers between the mentioned pre and post-operative time points.
|
Pre and post operatively (immediately before and after surgery, 24 and 48 hours after surgery)
|
Systemic immune response assessment by measurement of inflammatory mediators such as cytokines and nitric oxide metabolites.
Time Frame: Pre and postoperatively (immediately before and after surgery, 24 and 48 hours after surgery)
|
Inflammatory blood markers (MDA, isoprostanes, NO metabolites, Cytokines, adhesion molecules, among others)will be measured before surgery, immediately after surgery, 24 and 48 hours after surgery in order to establish changes in the markers between the mentioned pre and post-operative time points
|
Pre and postoperatively (immediately before and after surgery, 24 and 48 hours after surgery)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GN12KH253
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischaemic Reperfusion Injury
-
University of Cape TownUniversity College, London; Kenyatta National Hospital; Uganda Heart Institute; Grey's Hospital and other collaboratorsRecruitingMyocardial Reperfusion Injury | STEMI | Remote Ischaemic ConditioningKenya, Uganda, South Africa, Sudan
-
University of ChileFondo Nacional de Desarrollo Científico y Tecnológico, ChileCompletedReperfusion Injury | Acute Myocardial Infarction | Ischemia-reperfusion Injury | Reperfusion Injury, Myocardial | Reperfusion ArrhythmiasChile
-
University of AarhusErasmus Medical Center; Fonden til Lægevidenskabens FremmeCompletedIschemia Reperfusion Injury | Ischaemia Reperfusion InjuryDenmark
-
University of AarhusCompletedReperfusion Injuries, Myocardial
-
Indonesia UniversityEnrolling by invitationReperfusion Injury, MyocardialIndonesia
-
Chinese PLA General HospitalUnknown
-
West Kazakhstan Medical UniversityRecruitingKidney Transplantation | Ischemic Reperfusion Injury | ReperfusionKazakhstan
-
Cukurova UniversityCompleted
-
Chinese PLA General HospitalUnknownReperfusion Injury, Myocardial
-
Shahid Beheshti University of Medical SciencesPooyesh DarouCompletedMyocardial Ischemic Reperfusion InjuryIran, Islamic Republic of
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States